Stephen Patrick Anthony

Title: Innovations in Acute Myeloid Leukemia Treatment by Stephen Patrick Anthony

Introduction

Stephen Patrick Anthony is an accomplished inventor based in Heber City, Utah. He has made significant contributions to the field of oncology, particularly in the treatment of acute myeloid leukemia (AML). His innovative approaches aim to improve patient outcomes for those who have not responded to previous therapies.

Latest Patents

Stephen holds a patent for a novel treatment regimen for acute myeloid leukemia (AML) involving venetoclax failure. The patent outlines various regimens for treating AML in patients who have undergone prior anti-AML therapies and have shown disease progression. The treatment regimens include the use of alvocidib, either as a standalone therapy or in combination with cytarabine or hypomethylating agents like decitabine or azacitidine. Notably, these regimens do not involve combining alvocidib with venetoclax.

Career Highlights

Stephen is currently associated with Sumitomo Pharma Oncology, Inc., where he continues to develop innovative treatments for cancer. His work focuses on enhancing therapeutic options for patients suffering from AML, showcasing his commitment to advancing medical science.

Collaborations

Stephen has collaborated with notable colleagues in the field, including David J Bearss and Michael Vincent McCullar. These partnerships have contributed to the development of effective treatment strategies and have fostered a collaborative environment for research and innovation.

Conclusion

Stephen Patrick Anthony's contributions to the treatment of acute myeloid leukemia represent a significant advancement in oncology. His innovative patent and ongoing work at Sumitomo Pharma Oncology, Inc. highlight his dedication to improving patient care and outcomes in the fight against cancer.